Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC.
It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 23, 26 | -0.39 Decreased by -458.29% | -0.08 Decreased by -388.50% |
| Oct 28, 25 | -0.23 Decreased by -189.38% | -0.10 Decreased by -124.32% |
| Aug 11, 25 | -0.12 Decreased by -33.33% | -0.09 Decreased by -33.33% |
| Apr 29, 25 | -0.07 Decreased by -12.83% | -0.07 Increased by +0.73% |
| Feb 24, 25 | -0.07 Decreased by -16.67% | -0.08 Increased by +12.50% |
| Oct 30, 24 | -0.08 Decreased by -100.00% | -0.07 Decreased by -14.29% |
| Aug 6, 24 | -0.09 Decreased by -125.00% | -0.06 Decreased by -50.00% |
| Jun 14, 24 | -0.06 Decreased by -100.00% | -0.06 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -219.17 M Decreased by -258.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -231.79 M Decreased by -312.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -231.79 M Decreased by -283.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -62.91 M Decreased by -44.72% | Decreased by N/A% - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -61.20 M Decreased by -40.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Increased by +100.00% | -56.25 M Decreased by -53.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Increased by +100.00% | -60.38 M Decreased by -110.52% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | N/A Decreased by N/A% | -43.47 M Decreased by -104.41% | - - |